On January 17, 2025, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.), a Trop-2-directed antibody and topoisomerase inhibitor conjugate, for adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth fa
Data support the IGG signature, especially its key gene subset, as a potential marker of sustained antitumor activity in breast cancer.
Using immunotherapeutic agents like inotuzumab ozogamicin (InO), blinatumomab, or chimeric antigen receptor T (CAR T)-cell therapy in frontline adult B-cell acute lymphoblastic leukemia (B-ALL) the…
This video is a robotic right hepatectomy for multifocal/bilateral colorectal liver metastases. The left-sided lesions were previously treated. The video inc…
More than 18 000 US doctors have signed a letter calling on the Senate to reject Robert F Kennedy Jr as the federal secretary of…
Tallinn [Estonia], November 11 (ANI/Sputnik): The Estonian government approved on Thursday a draft law on public health, which, among other items, will ban tattoos and…
Inotuzumab ozogamicin (InO) is indicated for the treatment of adults with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL). This systematic literature review (CRD42022330496) assesse…
The ASTRO Fellow designation (FASTRO) is awarded based on length of ASTRO membership and commendable service to ASTRO and to the field of radiation oncology.
Friday, January 24, 2025, San Francisco, California, 6:00 PM – 8:00 PM Pacific Time (9:00 PM – 11:00 PM Eastern Time) Location San Francisco Marriott…
